Ono, Masafumi
Chichareon, Ply
Tomaniak, Mariusz
Kawashima, Hideyuki
Takahashi, Kuniaki
Kogame, Norihiro
Modolo, Rodrigo
Hara, Hironori
Gao, Chao
Wang, Rutao
Walsh, Simon
Suryapranata, Harry
da Silva, Pedro Canas
Cotton, James
Koning, René
Akin, Ibrahim
Rensing, Benno J. W. M.
Garg, Scot
Wykrzykowska, Joanna J.
Piek, Jan J.
Jüni, Peter
Hamm, Christian
Steg, Philippe Gabriel
Valgimigli, Marco
Windecker, Stephan
Storey, Robert F.
Onuma, Yoshinobu
Vranckx, Pascal
Serruys, Patrick W. http://orcid.org/0000-0002-9636-1104
Clinical trials referenced in this document:
Documents that mention this clinical trial
Characterization of quantitative flow ratio and fractional flow reserve discordance using doppler flow and clinical follow-up
https://doi.org/10.1007/s10554-022-02522-1
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) (Results)
https://doi.org/10.1136/bmjopen-2018-026053
Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
https://doi.org/10.1136/heartjnl-2015-309022
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention
https://doi.org/10.1161/circinterventions.120.009177
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
https://doi.org/10.1161/circoutcomes.120.006660
Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence
https://doi.org/10.1016/j.clinthera.2016.02.016
The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
https://doi.org/10.1007/s00392-020-01604-1
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
https://doi.org/10.1186/s12933-020-01153-x
Article History
Received: 3 December 2019
Accepted: 16 January 2020
First Online: 31 January 2020
Compliance with ethical standards
:
: Dr. Chichareon reports research grant from Biosensors outside the submitted work. Dr. Modolo received research grant from the Sao Paulo Research Foundation (FAPESP Grant Numer 2017/22013–8) and Biosensors. Dr. Piek reports personal fees and non-financial support from Philips/Volcano, outside the submitted work. Dr. Hamm reports personal fees from AstraZeneca, outside the submitted work. Dr. Steg reports grants and personal fees from Bayer/Janssen, grants and personal fees from Merck, grants and personal fees from Sanofi, grants and personal fees from Amarin, personal fees from Amgen, personal fees from Bristol Myers Squibb, personal fees from Boehringer-Ingelheim, personal fees from Pfizer, personal fees from Novartis, personal fees from Regeneron, personal fees from Lilly, personal fees from AstraZeneca, and grants and personal fees from Servier, outside the submitted work. Dr. Jüni reports research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. Dr. Storey reports personal fees from Bayer, personal fees from Bristol-Myers Squibb/Pfizer, grants and personal fees from AstraZeneca, personal fees from Novartis, personal fees from Idorsia, grants and personal fees from Thromboserin, personal fees from Haemonetics, personal fees from Amgen, grants and personal fees from Glycardial Diagnostics, personal fees from Portola, and personal fees from Medscape, outside the submitted work. Dr. Valgimigli reports personal fees from Astra Zeneca, grants and personal fees from Terumo, personal fees from Alvimedica/CID, personal fees from Abbott Vascular, personal fees from Daiichi Sankyo, personal fees from Opsens, personal fees from Bayer, personal fees from CoreFLOW, personal fees from IDORSIA PHARMACEUTICALS LTD, personal fees from Universität Basel | Dept. Klinische Forschung, personal fees from Vifor, personal fees from Bristol Myers Squib SA, and personal fees from iVascular, outside the submitted work. Dr. de Windecker received research and educational grants to the institution from Amgen, Abbott, Boston Scientific, Biotronik, Bayer, BMS, CSL Behring, Medtronic, Edwards Lifesciences, and Polares and Sinomed, outside the submitted work. Dr. Vranckx received personal fees from Astra Zeneca, personal fees from Bayer Health Care, personal fees from Daiichi Sankio, personal fees from Terumo, and personal fees from CLS Behring, outside the submitted work. Dr. Serruys reports personal fees from Biosensors, personal fees from Medtronic, personal fees from Micel Technologies, personal fees from Sinomedical Sciences Technology, personal fees from Philips/Volcano, personal fees from Xeltis, and personal fees from HeartFlow, outside the submitted work. All other authors declare no competing interests.